Jiangsu Hengrui Medicine Co., Ltd.
600276
Rang în acțiuni
#544
Jiangsu Hengrui Medicine Co., Ltd. is a global biopharmaceutical firm engaged... Jiangsu Hengrui Medicine Co., Ltd. is a global biopharmaceutical firm engaged in the full spectrum of pharmaceutical operations, from the initial discovery and development of medications to their manufacturing and worldwide distribution. The company is actively advancing a substantial pipeline of drug candidates, which includes Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403. These prospective treatments are aimed at a diverse range of medical conditions, primarily focusing on oncology, metabolic disorders, pain management, and autoimmune diseases, among others. The enterprise was founded in 1970 and maintains its corporate headquarters in Lianyungang, China.
Preț acțiune
$6.89
Capitalizare de piață
$43.94B
Schimbare (1 zi)
-2.91%
Schimbare (1 an)
-24.78%
Țară
CN
Tranzacționează Jiangsu Hengrui Medicine Co., Ltd. (600276)
Categorie
Healthcare
Venituri pentru Jiangsu Hengrui Medicine Co., Ltd. (600276)
Venituri în Oct 2026 TTM: 0
Conform celor mai recente rapoarte financiare ale Jiangsu Hengrui Medicine Co., Ltd., venitul actual al companiei (TTM) este 0. În anul 2026, compania a avut un venit de 0 egal cu venitul din anul 2026, care a fost de 0. Venitul reprezintă suma totală generată de o companie din vânzarea de bunuri sau servicii. Spre deosebire de profit, cheltuielile nu sunt scăzute.
Istoricul veniturilor pentru Jiangsu Hengrui Medicine Co., Ltd. din 2001 până în 2026
Venituri la sfârșitul fiecărui an
| An | Venituri | Schimbă |
|---|---|---|
| 2025 | $4.49B | 17.17% |
| 2024 | $3.83B | 18.93% |
| 2023 | $3.22B | 4.52% |
| 2022 | $3.08B | -24.33% |
| 2021 | $4.08B | -4.00% |
| 2020 | $4.25B | 26.94% |
| 2019 | $3.34B | 32.08% |
| 2018 | $2.53B | 19.08% |
| 2017 | $2.13B | 33.09% |
| 2016 | $1.60B | 11.38% |
| 2015 | $1.43B | 19.24% |
| 2014 | $1.20B | 17.65% |
| 2013 | $1.02B | 17.33% |
| 2012 | $871.59M | 20.75% |
| 2011 | $721.81M | 27.25% |
| 2010 | $567.25M | 27.86% |
| 2009 | $443.66M | 26.53% |
| 2008 | $350.63M | 30.64% |
| 2007 | $268.38M | 47.29% |
| 2006 | $182.22M | 24.73% |
| 2005 | $146.10M | 5.58% |
| 2004 | $138.38M | 9.03% |
| 2003 | $126.92M | 38.95% |
| 2002 | $91.34M | 19.17% |
| 2001 | $76.65M | 0.00% |
Venituri pentru companii similare sau concurente
| Companie | Venituri | Diferență de venituri | Țara |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $6.61B | - |
IN
|
